Sign In to View Organizational & Contract Pricing
Select a Size
About This Item
Empirical Formula (Hill Notation):
C22H23NO · HCl
CAS Number:
Molecular Weight:
353.89
MDL number:
UNSPSC Code:
51111800
PubChem Substance ID:
NACRES:
NA.77
Quality Level
Assay
≥98% (HPLC)
form
powder
storage condition
desiccated
color
white to beige
solubility
DMSO: 10 mg/mL, clear
storage temp.
2-8°C
SMILES string
Cl.O=C1C(=Cc2ccccc2)C(NC3CCCCC3)c4ccccc14
InChI
1S/C22H23NO.ClH/c24-22-19-14-8-7-13-18(19)21(23-17-11-5-2-6-12-17)20(22)15-16-9-3-1-4-10-16;/h1,3-4,7-10,13-15,17,21,23H,2,5-6,11-12H2;1H
InChI key
JPATUDRDKCLPTI-UHFFFAOYSA-N
Related Categories
Application
(E/Z)-BCI hydrochloride has been used:
- to evaluate the role of the Duox-H2O2-Dusp6 derepression signaling pathway in heart regeneration
- as an MKP-1 inhibitor to investigate the role of MKP-1 on bexarotent-induced effects
- as a dual specificity phosphatase 6 (DUSP6) inhibitor to study its effects on the proliferation of SKOV3 cells
Biochem/physiol Actions
(E/Z)-BCI Hydrochloride is an inhibitor of dual-specificity phosphatase 6 (Dusp6) and Dusp1; hyperactivates FGF signaling.
BCI is an allosteric inhibitor of Dusp6 that acts within the phosphatase domain to prevent the catalytic stimulation of phosphatase activity induced by ERK2 substrate binding. BCI also hyperactivates FGF signaling, since Dusp6 functions as a feedback regulator of FGF signaling.
Storage Class Code
11 - Combustible Solids
WGK
WGK 3
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
HE4 Compromises Cytotoxic Mononuclear Cells via Inducing Dual Specificity Phosphatase 6
James NE, et al.
Frontiers in Pharmacology, 10, 216-216 (2019)
Bexarotent attenuated CCI-induced spinal neuroinflammation and neuropathic pain by targeting MKP-1
Gui Y, et al.
The Journal of Pain : Official Journal of the American Pain Society (2019)
Guifang Gan et al.
Theranostics, 11(12), 6006-6018 (2021-04-27)
Objectives: Sorafenib is the only FDA-approved first-line target drug for HCC patients. However, sorafenib merely confers 3-5 months of survival benefit with less than 30% of HCC patients sensitive to sorafenib therapy. Thus, it's necessary to develop a sensitizer for
Yulong Gui et al.
The journal of pain, 21(11-12), 1149-1159 (2019-01-21)
It is widely accepted that neuroinflammation in the spinal cord contributes to the development of central sensitization in neuropathic pain. Mitogen-activated protein kinase (MAPK) activation plays a vital role in the development of neuroinflammation in the spinal cord. In this
Nicole E James et al.
Frontiers in pharmacology, 10, 216-216 (2019-04-04)
While selective overexpression of serum clinical biomarker Human epididymis secretory protein 4 (HE4) is indicative of ovarian cancer tumorigenesis, much is still known about the mechanistic role of the HE4 gene or gene product. Here, we examine the role of
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service